Literature DB >> 15679795

Risk factors in predicting a poor response to sildenafil citrate in elderly men with erectile dysfunction.

Kwanjin Park1, Ja Hyun Ku, Soo Woong Kim, Jae-Seung Paick.   

Abstract

OBJECTIVE: To assess the clinical efficacy of sildenafil and the potential predictors of poor response to sildenafil in elderly patients with erectile dysfunction (ED). PATIENTS AND METHODS: The study included 162 patients (aged > or = 60 years) treated with sildenafil for at least 8 weeks; all patients were evaluated with a history, physical examination, measurement of total testosterone and a pharmacological erection test. Sexual function before and 8 weeks after treatment was assessed using the self-administered International Index of Erectile Function (IIEF). Treatment was considered successful when the patient attained a higher grade on the erectile function (EF) domain score, and an affirmative response to the overall assessment question. Factors influencing treatment outcome were evaluated by univariate and multivariate statistical analysis.
RESULTS: The overall efficacy with sildenafil was 47% (76/162). On univariate analysis, uncontrolled diabetes, current smoking, hypogonadism (<3 microg/L testosterone) and low pretreatment EF domain score (<17) were selected as predictors of a poor response. On multivariate logistic regression, a low pretreatment EF domain score was the strongest independent prognostic factor for a poor response (odds ratio 2.25, 95% confidence interval, 1.45-7.33), and this was followed by hypogonadism (1.89, 1.12-3.16) and current smoking (1.34, 1.04-3.52).
CONCLUSION: In a real clinical setting, sildenafil was effective for about half of the elderly men. The baseline EF domain score, hypogonadism and current smoking were significantly associated with failure of sildenafil. These results suggest that modifying reversible risk factors, e.g. stopping smoking and replacing testosterone, would be beneficial in augmenting the efficacy of sildenafil in elderly men.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15679795     DOI: 10.1111/j.1464-410X.2005.05301.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  6 in total

1.  Impact of Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction in Men Taking Once-Daily Tadalafil 5 mg for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: An Integrated Analysis of Three Randomized Controlled Trials.

Authors:  John P Mulhall; Gerald B Brock; Sidney Glina; Simin Baygani; Craig F Donatucci; Mario Maggi
Journal:  J Sex Med       Date:  2016-03-24       Impact factor: 3.802

2.  Non-invasive management of primary phosphodiesterase type 5 inhibitor failure in patients with erectile dysfunction.

Authors:  Gregory Lowe; Robert Bahnson
Journal:  Ther Adv Urol       Date:  2009-12

Review 3.  Treatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido).

Authors:  Aksam A Yassin; Farid Saad
Journal:  World J Urol       Date:  2006-12       Impact factor: 3.661

4.  Erectile dysfunction and hypertension: impact on cardiovascular risk and treatment.

Authors:  Valter Javaroni; Mario Fritsch Neves
Journal:  Int J Hypertens       Date:  2012-05-09       Impact factor: 2.420

Review 5.  Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

Authors:  R Sadovsky; G B Brock; S W Gutkin; S Sorsaburu
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

6.  Hypogonadism and metabolic syndrome in nigerian male patients with both type 2 diabetes and hypertension.

Authors:  Oluyemi Akinloye; Bolutife Blessing Popoola; Mary Bolanle Ajadi; Joseph Gregory Uchechukwu; Dolapo Pius Oparinde
Journal:  Int J Endocrinol Metab       Date:  2014-01-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.